EI
AGRX

EAM Investors’s Agile Therapeutics AGRX Stock Holding History

EAM Investors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-164
Closed -$819K – 310
2019
Q4 		$819K Buy
+164
New +$573K 0.18% 219
2016
Q2 		– Sell
-66
Closed -$822K – 390
2016
Q1 		$822K Sell
66
-3
-4% -$38.7K 0.13% 273
2015
Q4 		$1.34M Buy
69
+1
+1% +$15.8K 0.17% 223
2015
Q3 		$920K Hold
68
– – 0.15% 269
2015
Q2 		$1.17M Hold
68
– – 0.14% 285
2015
Q1 		$1.26M Buy
+68
New +$1.19M 0.15% 271

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's AGRX Position: Q1 2020 in Review

EAM Investors sold out of Agile Therapeutics (AGRX) in Q1 2020, closing a stake of 164 shares — an estimated $819K sold.

EAM Investors first reported a position in AGRX in Q1 2015 and held it in 6 quarters. The position peaked at $1.34M in Q4 2015. 61 funds tracked by Wall St. Rank hold AGRX as of Q1 2020.

  • EAM Investors reported no remaining Agile Therapeutics position as of Q1 2020 after selling out during the quarter.
  • EAM Investors sold 164 Agile Therapeutics shares in Q1 2020, an estimated $819K.
  • EAM Investors first reported a position in Agile Therapeutics in Q1 2015 and held it in 6 quarters.
  • EAM Investors's Agile Therapeutics position peaked at $1.34M in Q4 2015.
  • 61 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2020.

Based on EAM Investors's 13F filing for Q1 2020, filed 13 May 2020.